IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
Clinical Trial Results: IMUNON's Phase 1 trial of its DNA plasmid vaccine, IMNN-101, demonstrated better six-month durability and immune response compared to mRNA vaccines against the Omicron XBB1.5 variant, with no serious adverse effects reported.
Strategic Partnership Goals: IMUNON is seeking strategic partners to advance its PlaCCine® technology platform, which offers advantages in vaccine stability, manufacturing flexibility, and potential applications for COVID-19 and other infectious diseases.
Trade with 70% Backtested Accuracy
Analyst Views on IMNN
About IMNN
About the author
IMUNON Secures $7 Million from Institutional Investor in Direct Stock Offering
- Financing Agreement Reached: IMUNON has entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 1,939,114 shares of common stock and associated warrants, with expected gross proceeds of approximately $7 million, enhancing the company's liquidity to support its clinical-stage immunotherapy development.
- Warrant Details: Each share is priced at $3.61, with warrants having an exercise price of $3.482, which will be exercisable immediately and expire in five years, providing the company with additional capital sources to drive future R&D efforts.
- Market Reaction Anticipated: The offering is expected to close on December 31, 2025, and if successful, will help IMUNON maintain compliance with Nasdaq requirements and avoid potential delisting risks, thereby boosting investor confidence.
- Registration Statement Background: The securities are being offered under a Form S-3 registration statement declared effective on May 22, 2024, ensuring compliance and laying the groundwork for future financing activities, demonstrating the company's flexibility and adaptability in capital markets.
IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy
- Significant Clinical Progress: IMUNON initiated its pivotal Phase 3 OVATION3 study in 2025, evaluating IMNN-001 in combination with standard chemotherapy, demonstrating strong clinical momentum that could redefine treatment standards for ovarian cancer.
- Survival Extension: The Phase 2 OVATION2 study revealed a 13-month median overall survival extension in the intent-to-treat population with IMNN-001, and in patients receiving PARP inhibitors, the median survival has not yet been reached, indicating its potential therapeutic advantage.
- Immunotherapy Promise: New data indicates that IMNN-001 activates the tumor microenvironment, leading to IL-12 production and enhanced T cell functions, showcasing its broad applicability in frontline ovarian cancer treatment.
- Financial Discipline: IMUNON maintained financial discipline in 2025, planning to invest $30 million in the OVATION3 trial, reflecting the company's confidence in its R&D and market opportunities.
IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy
- Significant Clinical Progress: IMUNON initiated its pivotal Phase 3 OVATION 3 study in 2025, evaluating IMNN-001 in combination with standard chemotherapy, demonstrating strong clinical outcomes that could redefine treatment standards for ovarian cancer.
- Survival Extension: In the Phase 2 OVATION 2 study, IMNN-001 showed a 13-month median overall survival extension in the intent-to-treat population, with survival not yet reached in patients receiving PARP inhibitors, indicating its potential in ovarian cancer treatment.
- Promise of Immunotherapy: New data indicates that IMNN-001 activates macrophages in the tumor microenvironment, leading to IL-12 production and enhanced T cell cytotoxic functions, showcasing its promise as a frontline therapy.
- Financial Discipline: IMUNON maintained financial discipline in 2025, planning to invest $30 million in the OVATION 3 trial, reflecting the company's confidence in future growth and commitment to shareholder value.
Imunon (IMNN) Q3 2025 Earnings Conference Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
IMUNON Releases Financial Results for Q3 2025 and Offers Business Update
R&D Day Highlights: IMUNON showcased significant progress in its Phase 3 OVATION 3 Study for IMNN-001, a potential frontline immunotherapy for advanced ovarian cancer, emphasizing strong survival data and a favorable safety profile.
Financial Performance: The company reported a net loss of $3.4 million for Q3 2025, a decrease from the previous year, with operating expenses also down by 30%, indicating improved financial management.
Clinical Advancements: IMNN-001 demonstrated the ability to create a "hot" tumor microenvironment, enhancing immune responses and showing promising results in ongoing clinical trials, including a notable median overall survival benefit.
PlaCCine Technology Development: IMUNON is advancing its PlaCCine DNA vaccine technology, presenting positive proof-of-concept data at various conferences, and is seeking partnerships to enhance its vaccine development efforts.
IMUNON's Public Webcast Showcases Resilience and Innovation in the Quest for the First Approved Ovarian Cancer Immunotherapy
Webcast Event: IMUNON, Inc. hosted a public webcast featuring cancer experts discussing the potential of their DNA-mediated immunotherapy, IMNN-001, for treating advanced ovarian cancer, with recordings and slides available on their website.
Company Overview: IMUNON is a clinical-stage biotechnology company focused on innovative treatments using non-viral DNA technology, including their lead program IMNN-001 and a COVID-19 booster vaccine (IMNN-101).
Clinical Trials: IMNN-001 has completed a Phase 2 trial and is currently in Phase 3 trials, demonstrating the company's commitment to advancing therapies for difficult-to-treat conditions.
Forward-Looking Statements: The company issued a caution regarding forward-looking statements, highlighting the risks and uncertainties associated with clinical trials and the development of their therapies.
IMUNON Secures $7 Million from Institutional Investor in Direct Stock Offering
- Financing Agreement Reached: IMUNON has entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 1,939,114 shares of common stock and associated warrants, with expected gross proceeds of approximately $7 million, enhancing the company's liquidity to support its clinical-stage immunotherapy development.
- Warrant Details: Each share is priced at $3.61, with warrants having an exercise price of $3.482, which will be exercisable immediately and expire in five years, providing the company with additional capital sources to drive future R&D efforts.
- Market Reaction Anticipated: The offering is expected to close on December 31, 2025, and if successful, will help IMUNON maintain compliance with Nasdaq requirements and avoid potential delisting risks, thereby boosting investor confidence.
- Registration Statement Background: The securities are being offered under a Form S-3 registration statement declared effective on May 22, 2024, ensuring compliance and laying the groundwork for future financing activities, demonstrating the company's flexibility and adaptability in capital markets.
IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy
- Significant Clinical Progress: IMUNON initiated its pivotal Phase 3 OVATION3 study in 2025, evaluating IMNN-001 in combination with standard chemotherapy, demonstrating strong clinical momentum that could redefine treatment standards for ovarian cancer.
- Survival Extension: The Phase 2 OVATION2 study revealed a 13-month median overall survival extension in the intent-to-treat population with IMNN-001, and in patients receiving PARP inhibitors, the median survival has not yet been reached, indicating its potential therapeutic advantage.
- Immunotherapy Promise: New data indicates that IMNN-001 activates the tumor microenvironment, leading to IL-12 production and enhanced T cell functions, showcasing its broad applicability in frontline ovarian cancer treatment.
- Financial Discipline: IMUNON maintained financial discipline in 2025, planning to invest $30 million in the OVATION3 trial, reflecting the company's confidence in its R&D and market opportunities.
IMUNON Advances OVATION3 Study, Aiming for Breakthrough Therapy
- Significant Clinical Progress: IMUNON initiated its pivotal Phase 3 OVATION 3 study in 2025, evaluating IMNN-001 in combination with standard chemotherapy, demonstrating strong clinical outcomes that could redefine treatment standards for ovarian cancer.
- Survival Extension: In the Phase 2 OVATION 2 study, IMNN-001 showed a 13-month median overall survival extension in the intent-to-treat population, with survival not yet reached in patients receiving PARP inhibitors, indicating its potential in ovarian cancer treatment.
- Promise of Immunotherapy: New data indicates that IMNN-001 activates macrophages in the tumor microenvironment, leading to IL-12 production and enhanced T cell cytotoxic functions, showcasing its promise as a frontline therapy.
- Financial Discipline: IMUNON maintained financial discipline in 2025, planning to invest $30 million in the OVATION 3 trial, reflecting the company's confidence in future growth and commitment to shareholder value.
Imunon (IMNN) Q3 2025 Earnings Conference Call Transcript
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
IMUNON Releases Financial Results for Q3 2025 and Offers Business Update
R&D Day Highlights: IMUNON showcased significant progress in its Phase 3 OVATION 3 Study for IMNN-001, a potential frontline immunotherapy for advanced ovarian cancer, emphasizing strong survival data and a favorable safety profile.
Financial Performance: The company reported a net loss of $3.4 million for Q3 2025, a decrease from the previous year, with operating expenses also down by 30%, indicating improved financial management.
Clinical Advancements: IMNN-001 demonstrated the ability to create a "hot" tumor microenvironment, enhancing immune responses and showing promising results in ongoing clinical trials, including a notable median overall survival benefit.
PlaCCine Technology Development: IMUNON is advancing its PlaCCine DNA vaccine technology, presenting positive proof-of-concept data at various conferences, and is seeking partnerships to enhance its vaccine development efforts.
IMUNON's Public Webcast Showcases Resilience and Innovation in the Quest for the First Approved Ovarian Cancer Immunotherapy
Webcast Event: IMUNON, Inc. hosted a public webcast featuring cancer experts discussing the potential of their DNA-mediated immunotherapy, IMNN-001, for treating advanced ovarian cancer, with recordings and slides available on their website.
Company Overview: IMUNON is a clinical-stage biotechnology company focused on innovative treatments using non-viral DNA technology, including their lead program IMNN-001 and a COVID-19 booster vaccine (IMNN-101).
Clinical Trials: IMNN-001 has completed a Phase 2 trial and is currently in Phase 3 trials, demonstrating the company's commitment to advancing therapies for difficult-to-treat conditions.
Forward-Looking Statements: The company issued a caution regarding forward-looking statements, highlighting the risks and uncertainties associated with clinical trials and the development of their therapies.
